A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
AIMS: Glycemic control is important for preventing diabetic retinopathy (DR), but rapid improvements could deteriorate the disease. In some, but not all studies, semaglutide is speculated to worsen DR, but the mechanism is unknown. Central retinal th…
BACKGROUND AND AIMS: Weight recidivism following sleeve gastrectomy (SG) is common. Adjuvant treatments include new glucagon-like peptide 1 and glucose-dependent insulinotropic peptide receptor agonists (GLP1/GIP-RA) or revisional endoscopic sleeve g…
Glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1 RAs) are widely used as antidiabetic and anti-obesity agents. Although conventional GLP-1 RAs, such as liraglutide and semaglutide, are acylated with fatty acids to delay their degradation by d…
Diabetes is now a global chronic disease, with the number of people with diabetes expected to reach 643 million by the end of 2030. Semaglutide, a human glucagon-like peptide-1 (GLP-1) analogue with 94% similarity to human GLP-1, can promote insulin…
AIMS: Glucagon-like peptide-1 (GLP-1) receptor agonists, alongside dual receptor agonists targeting glucose-dependent insulinotropic polypeptide (GIP) receptors, represent transformative therapies for obesity management. Despite their increasing use,…
Semaglutide and liraglutide are long-acting glucagon-like peptide-1 receptor agonists used to treat type-2 diabetes and obesity. Recent advances in peptide synthesis and analytical technologies have enabled the development of synthetic generic peptid…
Causal mediation analysis is an important tool in medical research, enabling researchers to examine and quantify the mechanisms through which a treatment exerts its effects on an outcome of interest. In many studies, the potential mediator is measure…
This study aimed to systematically review existing evidence on the preoperative use of GLP-1 receptor agonists (GLP-1 RA) before metabolic and bariatric surgery (MBS). Web of Science, Embase, PubMed, and Scopus were searched systematically with relev…
CONTEXT: Relationship between obesity and the sense of taste is complex, with many inconsistent and conflicting findings that are largely methodology dependent. The impact of glucagon-like peptide-1 analogues on taste remains largely unaddressed. MET…
Neuroendocrine neoplasms (NENs) represent a heterogeneous group of malignancies that consist of two major subtypes: neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs). Glucagon-like peptide-1 receptor agonists (GLP-1Ra) have demonstrat…
: Since the introduction of the first GLP-1 receptor agonist (GLP-1 RA) in 2005, there has been a steady increase in the number of drugs available in this group, as well as an expansion of their indications and routes of administration.: The aim of t…
CONTEXT: The use of glucagon-like peptide-1 receptor (GLP-1R) agonists such as semaglutide, a novel class of antidiabetic medications, has raised concerns about potential adverse effects, particularly a possible association with thyroid cancer (TC).…
Type 2 Diabetes Mellitus therapy has evolved over the years to now include a new class of therapeutics, semaglutide. This article reviews the mechanism of action and formulation of semaglutide therapy, potential benefits, contraindications, adverse e…
OBJECTIVE: In this post hoc analysis, we used the data from the Adjunct Semaglutide Treatment in Type 1 Diabetes (ADJUST-T1D) trial, a double-blind, multicenter, randomized, placebo-controlled trial of semaglutide 1 mg/week in adults with type 1 diab…
Aneurysmal Subarachnoid Hemorrhage (SAH) is a devastating cerebrovascular event with high morbidity and mortality rates, and early brain injury following SAH (EBI-SAH) within 72 h leads to a poor prognosis. Despite advances in our understanding of th…